MmpL3 Inhibitor Compounds Targeting Mycobacterial Cell Wall
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mycobacterial infections, such as tuberculosis, face challenges due to the unique cell wall structure of Mycobacterium tuberculosis, which makes it resistant to many chemical disinfectants and difficult to target with conventional antibiotics, necessitating the development of specific inhibitors for the MmpL3 protein to effectively combat the infection.
Innovation Solution
Development of compounds that inhibit the activity of MmpL3, specifically those represented by Formula I and their pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, or mixtures thereof, which target the mycobacterial membrane protein MmpL3 to treat and prevent mycobacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat mycobacterial infections, then treatment is attempted, but the unique cell wall structure containing mycolic acid makes the bacteria resistant and the treatment ineffective
Solution Approach 1:
The patent changes the chemical parameters of the treatment approach by developing compounds with specific molecular structures (Formula I) that can penetrate the unique mycolic acid-containing cell wall. The compounds feature specific structural parameters including heteroaryl rings, linker groups, and substituent patterns that enable them to overcome the physical barrier of the cell wall and achieve effective concentrations at the target MmpL3 protein.
2Reliability
If the cell wall structure with mycolic acid is maintained for bacterial survival, then bacterial pathogenicity is preserved, but this same structure resists chemical disinfectants and conventional antibiotics
Solution Approach 1:
The patent introduces compounds of Formula I as intermediary substances that facilitate the delivery of therapeutic effect across the resistant cell wall barrier. These compounds act as mediators by first penetrating through the mycolic acid layer via their specific hydrophobic-hydrophilic balance, then delivering the inhibitory effect to the MmpL3 protein, thus bridging the gap between the external environment and the protected bacterial targets.
3Reliability
If MmpL3 protein function is maintained for mycolic acid transport, then bacterial growth is supported, but this makes MmpL3 an essential target for developing new anti-mycobacterial agents
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at different positions: the heteroaryl ring portion interacts with specific binding pockets of MmpL3, the linker group provides appropriate spacing and orientation, and the substituent groups (R1-R6) provide local interactions that enhance binding affinity and selectivity for MmpL3 over other bacterial proteins.
Data Source
AI summary
The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.